Stockreport

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report
PDF – Part 2 of REFRaME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 p [Read more]